Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionJefferies Financial Group Inc.
Latest Disclosed Ownership23,810 shares
Latest Disclosed Value $ 10,632,117
Jefferies Financial Group Inc. ownership in VRTX / Vertex Pharmaceuticals Incorporated

On May 7, 2026 - Jefferies Financial Group Inc. filed a 13F-HR form disclosing ownership of 23,810 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $10,632,117 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 9, 2026 disclosing 31,372 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -24.10% during the quarter. The current value of the position is $10,517,829 USD.

Jefferies Financial Group Inc. has a history of taking positions in derivatives of the underlying security (VRTX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 23,810 -7,562 -24.10 10,632 -25.24 0.0728
2026-02-09 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 31,372 15,372 96.08 14,223 126.97 0.0727
2025-11-13 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 16,000 -18,615 -53.78 6,266 -59.34 0.0296
2025-08-12 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 34,615 15,131 77.66 15,411 63.14 0.1295
2025-05-08 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 19,484 5,500 39.33 9,446 67.75 0.0834
2025-02-27 2024-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 13,984 -18,659 -57.16 5,631 -62.91 0.0337
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,984 -18,659 5,631 0.0335
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 32,643 -27,632 -45.84 15,182 -46.27 0.1086
2024-08-13 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 60,275 3,453 6.08 28,252 18.95 0.3001
2024-05-13 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 56,822 38,814 215.54 23,752 224.17 0.2194
2024-05-06 2023-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 18,008 17,707 5,882.72 7,327 6,945.19 0.0478
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 18,008 17,707 7,327 0.0478
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 301 -10,632 -97.25 105 -97.30 0.0009
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,933 -191 -1.72 3,847 9.79 0.0345
2023-05-15 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,124 3,636 48.56 3,505 62.07 0.0283
2023-09-21 2022-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 7,488 7,488 2,162 0.0150
2023-02-14 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,222 11,222 2,156 0.0149
2016-08-12 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -3,300 -100.00 0 -100.00
2016-05-16 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,300 3,300 262 0.0369
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2024-05-13 2024-03-31 13F VERTEX PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-05-06 2023-12-31 13F/A VERTEX PHARMACEUTICALS COM Call 12,400 37.78 5,045 61.23 n/a n/a n/a
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM Call 12,400 5,045 n/a n/a n/a
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM Call 9,000 -10.89 3,130 -11.96 n/a n/a n/a
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM Call 10,100 3,554 n/a n/a n/a
2023-05-15 2023-03-31 13F VERTEX PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2023-09-21 2022-12-31 13F/A VERTEX PHARMACEUTICALS COM Call 5,200 1,502 n/a n/a n/a
2023-02-14 2022-12-31 13F VERTEX PHARMACEUTICALS COM Call 5,200 1,502 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2024-05-13 2024-03-31 13F VERTEX PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-05-06 2023-12-31 13F/A VERTEX PHARMACEUTICALS COM Put 8,900 128.21 3,621 167.04 n/a n/a n/a
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM Put 8,900 3,621 n/a n/a n/a
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM Put 3,900 1,200.00 1,356 1,191.43 n/a n/a n/a
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM Put 300 -98.50 106 -98.33 n/a n/a n/a
2023-05-15 2023-03-31 13F VERTEX PHARMACEUTICALS COM Put 20,000 -0.99 6,301 8.02 n/a n/a n/a
2023-09-21 2022-12-31 13F/A VERTEX PHARMACEUTICALS COM Put 20,200 5,833 n/a n/a n/a
2023-02-14 2022-12-31 13F VERTEX PHARMACEUTICALS COM Put 20,200 5,833 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.